Care Delivery

This channel includes news on cardiovascular care delivery, including how patients are diagnosed and treated, cardiac care guidelines, policies or legislation impacting patient care, device recalls that may impact patient care, and cardiology practice management.

Thumbnail

1 in 3 cardiologists have been sued, though they often win when it happens

Overall, 31.2% of U.S. physicians say they have been sued. When looking at only cardiologists, the percentage is slightly higher.

Samsung galaxy smartwatch showing atrial fibrillation (AFib) alerts

FDA clears AFib alerts for Samsung smartwatches

Samsung's smartwatches, already equipped with ECG technology, will now be able to alert users when signs of an irregular heart rhythm are detected. 

Thumbnail

How improving access to PCI affects heart attack outcomes

When PCI-capable hospitals open and close, how does it impact patient care for the surrounding area? Researchers aimed to find out, sharing their findings in JACC: Cardiovascular Interventions.

female physician male

Fewer stress tests, more high-risk procedures: How working at a hospital influences cardiologists

Cardiologists employed by a hospital appear to be more likely to pursue cardiac catheterization or angioplasty than independent cardiologists.

MAUDE database medical device safety

Risk points revealed in US database of AI-powered medical devices

Researchers analyzed 266 safety events reported to the FDA’s Manufacturer and User Facility Device Experience (“Maude”) program.

Thumbnail

New CMS code could pave the way for coverage of virtual reality-based treatments

The determination places the device under the Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) benefit category. 

ChatGPT bests physicians at patient care

AI outplays physicians at informing patients and feeling their pain too

Unexpected empathy: Blinded healthcare professionals consistently scored the AI—yes, a ChatGPT model—higher than the doctors even for bedside manners.

The FDFA has cleared tirzepatide (Mounjaro) from Eli Lilly for the treatment of diabetes.

Eli Lilly targets FDA approval for weight loss medication

Tirzepatide, sold under the name Mounjaro, is among a handful of drugs with big buzz for their weight loss results, and approval for obesity could be a huge revenue source for Eli Lilly in the future.